Wolfson Centre for Age-Related Diseases, King's College London, London, UK.
Lancet. 2011 Mar 19;377(9770):1019-31. doi: 10.1016/S0140-6736(10)61349-9. Epub 2011 Mar 1.
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.
全球估计有 2400 万人患有痴呆症,其中大多数人被认为患有阿尔茨海默病。因此,阿尔茨海默病是一个主要的公共卫生关注点,并已被确定为研究重点。尽管有许可的治疗方法可以缓解阿尔茨海默病的症状,但迫切需要更好地了解发病机制,以开发能够改变疾病进程的治疗方法。改进诊断方法的方法也在不断推进,但需要更好的共识来开发一组支持临床诊断的生物学和神经影像学生物标志物。现在有强有力的证据表明阿尔茨海默病、痴呆症和认知能力下降的潜在风险和保护因素,但需要进一步研究以更好地了解这些因素,并确定干预措施是否可以显著降低这些风险。在本次研讨会上,我们概述了最近关于阿尔茨海默病的流行病学、发病机制、诊断和治疗的证据,并讨论了降低发病风险的潜在方法。